5.2.7.3.α1-blockers + beta-3 agonist. mechanism action: combination therapy consists α1-blocker (section 5.2.1) together beta-3-agonist (section 5.2.4) add-on therapy males receiving α1-blockers persisting oab symptoms. efficacy: match study explored effect addition mirabegron 50 mg tamsulosin 0.2 mg compared tamsulosin plus placebo 544 patients . statistically significant difference 0.52 voids per day seen favour mirabegron. total ipss score also improved significant groups. another rct evaluated add-on therapy mirabegron oab symptoms persisting treatment tamsulosin 0.2 mg daily men bpo . combination therapy associated greater improvements oab symptom score, urinary urgency daytime frequency well storage sub-score ipss qol index compared monotherapy tamsulosin . plus phase iv trial compared mirabegron placebo population males treated standard dose tamsulosin 0.4 mg. four-week run-in period treatment tamsulosin 0.4 mg alone, 715 patients randomised placebo mirabegron 25 mg, upgraded 50 mg one month. mean number micturition’s significantly reduced experimental arm, effect size deemed low (mean adjusted difference 0.39 voids per day). similar results seen mean voided volume urgency episodes, total ipss, ipss sub-scores oab-q symptom score significantly different groups. rct comparing efficacy mirabegron 50 mg fesoterodine 4 mg add-on therapy silodosin luts patients persisting oab symptoms reported three months, fesoterodine add-on therapy showed significantly greater improvement mirabegron add-on therapy oab symptom score urgency score ipss-qol score . fesoterodine also superior alleviating do. tolerability safety: match study main adverse events line previous trials, cardiovascular events uncommon studied populations . plus phase iv trial also reported adverse events similar seen previous trials (hypertension, headache nasopharyngitis frequent) . six episodes retention recorded (1.7%) overall, clinically significant specific change seen qmax pvr. open-label, randomised, 2-arm, 2-sequence study reported addition mirabegron tamsulosin patients tamsulosin mirabegron mono therapy cause clinically relevant changes cardiovascular safety safety profiles . solifenacin mirabegron also compared another rct shown comparable efficacy better safety profile mirabegron . practical consideration: add-on therapy mirabegron patients remaining symptoms α1-blocker therapy evaluated short-term clinical trials. short-term benefit remains uncertain low effect size urinary frequency compared placebo, studies longer follow-up required summary evidencelecombination treatment α1-blockers mirabegron results slight decrease number voids urgency episodes per day compared α1-blockers alone.1badverse events drug classes seen combined treatment using α1-blockers mirabegron.1b recommendationsstrength ratinguse combination treatment α1-blocker mirabegron patients persistent storage luts treatment α1-blocker monotherapy.weak